Claims
- 1. A compound having the general formula ##STR3## wherein: R.sup.1 is hydrogen or C.sub.1 -C.sub.2 alkyl;
- R.sup.2 is hydrogen or C.sub.1 -C.sub.3 alkyl;
- R.sup.3 is C.sub.1 -C.sub.4 alkyl or phenyl C.sub.1 -C.sub.4 alkyl;
- R.sup.4 is C.sub.1 -C.sub.8 alkyl;
- R.sup.5 is C.sub.6 -C.sub.10 alkyl;
- R.sup.6 is hydrogen, hydroxy, halogen, nitro, C.sub.1 -C.sub.3 alkoxy, or C.sub.1 -C.sub.3 alkyl; and
- X is a therapeutically acceptable anion.
- 2. The compound of claim 1 wherein R.sup.3 is C.sub.1 -C.sub.4 alkyl and R.sup.6 is halogen, nitro, C.sub.1 -C.sub.3 alkoxy, or C.sub.1 -C.sub.3 alkyl.
- 3. The compound according to claim 1, said compound being N,N-diethyl-N-n-heptyl-4-phenylbutylammonium bromide.
- 4. The compound according to claim 1, said compound being N,N-dimethyl-N-n-octyl-4-phenylbutylammonium bromide.
- 5. The compound according to claim 1, said compound being N,N-dimethyl-N-n-hexyl-4-phenylbutylammonium bromide.
- 6. The compound according to claim 1, said compound being N,N-dimethyl-N-n-heptyl-1-methyl-4-phenylbutylammonium bromide.
- 7. The compound according to claim 1, said compound being N,N-dimethyl-N-sec-octyl-4-phenylbutylammonium bromide.
- 8. The compound of claim 1 wherein R.sup.6 is halogen or nitro.
- 9. The compound according to claim 8, said compound being N,N-diethyl-N-n-heptyl-4-(4-chlorophenyl)butylammonium bromide.
- 10. The compound according to claim 8, said compound being N,N-diethyl-N-n-heptyl-4-(4-(4-nitrophenyl)butylammonium bromide.
- 11. The compound according to claim 8, said compound being N,N-diethyl-N-n-heptyl-4-(4-chlorophenyl)butylammonium phosphate.
- 12. The compound of claim 1 wherein R.sup.3 and R.sup.4 both are C.sub.1 -C.sub.2 alkyl.
- 13. The compound of claim 1 wherein R.sup.3 and R.sup.4 both are methyl and R.sup.5 is n-hexyl or n-heptyl.
- 14. The compound of claim 1 wherein R.sup.3 and R.sup.4 both are ethyl and R.sup.5 is n-hexyl or n-heptyl.
- 15. The compound of claim 1 wherein R.sup.3 is C.sub.1 -C.sub.2 alkyl and R.sup.4 is C.sub.4 -C.sub.5 alkyl.
- 16. The compound of claim 1 wherein R.sup.1 is C.sub.1 -C.sub.2 alkyl and R.sup.2 is hydrogen.
- 17. The compound of claim 1 wherein R.sup.1 is methyl, R.sup.2 is hydrogen, R.sup.3 and R.sup.4 are C.sub.1 -C.sub.2 alkyl, R.sup.5 is C.sub.6 -C.sub.7 alkyl and R.sup.6 is other than hydrogen.
- 18. The compound of claim 1 wherein R.sup.1 and R.sup.2 are hydrogen, R.sup.3 and R.sup.4 independently are C.sub.1 -C.sub.2 alkyl, R.sup.6 is halogen or nitro, and X.sup.- is phosphate.
- 19. A method of treating re-entrant arrhythmias comprising administering to a subject in need thereof an antiarrhythmically effective dose of a compound of claim 1.
- 20. The method according to claim 19 employing the compound wherein R.sup.3 is C.sub.1 -C.sub.4 alkyl and R.sup.6 is hydrogen, halogen, nitro, C.sub.1 -C.sub.3 alkoxy, or C.sub.1 -C.sub.3 alkyl.
- 21. The method according to claim 19 employing the compound wherein R.sup.1 is hydrogen or methyl, R.sup.2 is hydrogen, R.sup.3 is C.sub.1 -C.sub.2 alkyl, R.sup.4 is C.sub.1 -C.sub.2 alkyl, and R.sup.6 is other than hydrogen.
- 22. The method according to claim 19 wherein the compound administered is N,N-diethyl-N-n-heptyl-4-(4-chlorophenyl)butylammonium bromide.
- 23. The method according to claim 19 wherein the compound administered is N,N-diethyl-N-n-heptyl-4-(4-chlorophenyl)butylammonium phosphate.
- 24. A pharmaceutical formulation useful in the treatment of re-entrant arrhythmias in humans comprising as active ingredient an antiarrhythmic amount of a quaternary ammonium salt defined in claim 1 in combination with one or more pharmaceutically acceptable diluents or carriers thereof.
- 25. The formulation of claim 24 employing the active ingredient wherein R.sup.3 is C.sub.1 -C.sub.4 alkyl, and R.sup.6 is hydrogen, halogen, nitro, C.sub.1 -C.sub.3 alkoxy or C.sub.1 -C.sub.3 alkyl.
- 26. The formulation according to claim 25 employing the active ingredient of the formula
- R.sup.1 is hydrogen or methyl;
- R.sup.2 is hydrogen;
- R.sup.3 is C.sub.1 -C.sub.2 alkyl;
- R.sup.4 is C.sub.1 -C.sub.2 alkyl;
- R.sup.6 is hydrogen, C.sub.1 -C.sub.3 alkoxy, C.sub.1 -C.sub.3 alkyl or nitro, and
- X is a therapeutically acceptable anion.
- 27. The formulation according to claim 25 wherein the active ingredient is N,N-diethyl-N-n-heptyl-4-(4-chlorophenyl)butylammonium bromide.
- 28. The formulation according to claim 25 wherein the active ingredient is N,N-diethyl-N-n-heptyl-4-(4-chlorophenyl)butylammonium phosphate.
CROSS-REFERENCE TO RELATED APPLICATIONS
This is a continuation-in-part of Ser. No. 861,789, filed Dec. 19, 1977 now abandoned.
US Referenced Citations (4)
Non-Patent Literature Citations (3)
Entry |
Pharmac 37, 555-584, 1969--Barlow et al. |
European J. of Pharm. 35 (1976), 245-252--Lien et al. |
Chem. Abst. 54, 19588(f) (1960)--Morikawa. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
861789 |
Dec 1977 |
|